Use of RapidChek® SELECT™ Salmonella to detect shedding of live attenuated Salmonella enterica serovar Typhi vaccine strains

Journal of Microbiological Methods

Volumn 89, Issue 2, 2012, Pages 137-147

  Brenneman, Karen E ^a   McDonald, Caitlin ^a   Kelly Aehle, Sandra M ^b   Roland, Kenneth L ^a   Curtiss, Roy ^a,c  

^a ARIZONA STATE UNIVERSITY   (United States)

^b Lohmann Integrated Solutions   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Detection; LPS; O antigen; RapidChek SELECT Salmonella; Salmonella Typhi; Shedding

Indexed keywords

LIPOPOLYSACCHARIDE; MEASLES VACCINE; TYPHOID VACCINE;

ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL SHEDDING; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM CULTURE; BACTERIUM DETECTION; CONTROLLED STUDY; GENE MUTATION; MICROORGANISM; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA TYPHI; SALMONELLOSIS; SENSITIVITY ANALYSIS; SEROTYPE; WILD TYPE;

BACTERIAL SHEDDING; BACTERIOLOGICAL TECHNIQUES; BACTERIOPHAGES; HUMAN EXPERIMENTATION; HUMANS; SALMONELLA TYPHI; SENSITIVITY AND SPECIFICITY; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

SALMONELLA; SALMONELLA ENTERICA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI; SALMONELLA TYPHI;

EID: 84859051128     PISSN: 01677012     EISSN: 18728359     Source Type: Journal    
DOI: 10.1016/j.mimet.2012.03.001     Document Type: Article

References (49)

1. Anonymous Reactivity profiles for RapidChek® SELECT™ for Salmonella. Technical Bulletin SELECT #1 2007, 1-5. Strategic Diagnostics, Inc.
2. Bertani G. Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli. J. Bacteriol. 1951, 62:293-300.
3. Bittner M., Saldias S., Estevez C., Zaldivar M., Marolda C.L., Valvano M.A., Contreras I. O-antigen expression in Salmonella enterica serovar Typhi is regulated by nitrogen availability through RpoN-mediated transcriptional control of the rfaH gene. Microbiology 2002, 148:3789-3799.
4. Bravo D., Silva C., Carter J.A., Hoare A., Alvarez S.A., Blondel C.J., Zaldivar M., Valvano M.A., Contreras I. Growth-phase regulation of lipopolysaccharide O-antigen chain length influences serum resistance in serovars of Salmonella. J. Med. Microbiol. 2008, 57:938-946.
5. Buchwald D.S., Blaser M.J. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev. Infect. Dis. 1984, 6:345-356.
6. Collins L.V., Attridge S., Hackett J. Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice. Infect. Immun. 1991, 59:1079-1085.
7. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 2010, 50:241-246.
8. Curtiss R. Bacterial infectious disease control by vaccine development. J. Clin. Invest. 2002, 110:1061-1066.
9. Curtiss R., Zhang X., Wanda S.Y., Kang H.Y., Konjufca V., Li Y., Gunn B., Wang S., Scarpellini G., Lee I.S. Induction of host immune responses using Salmonella-vectored vaccines. Virulence Mechanisms of Bacterial Pathogens 2007, 297-313. ASM Press, Washington, D.C. K.A. Brogden (Ed.).
10. Curtiss R., Wanda S.Y., Gunn B.M., Zhang X., Tinge S.A., Ananthnarayan V., Mo H., Wang S., Kong W. Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect. Immun. 2009, 77:1071-1082.
11. Felix A., Pitt R.M. Virulence and immunogenic activities of B. typhosus in relation to its antigenic constituents. J. Hyg. (Lond.) 1935, 35:428-436.
12. Frey S.E., Bollen W., Sizemore D., Campbell M., Curtiss R. Bacteremia associated with live attenuated χ8110 Salmonella enterica serovar Typhi ISP1820 in healthy adult volunteers. Clin. Immunol. 2001, 101:32-37.
13. Germanier R., Fürer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 1975, 131:553-558.
14. Germanier R., Fürer E. Characteristics of the attenuated oral vaccine strain "S. typhi" Ty 21a. Dev. Biol. Stand. 1983, 53:3-7.
15. Gilman R.H., Hornick R.B., Woodard W.E., DuPont H.L., Snyder M.J., Levine M.M., Libonati J.P. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine. J. Infect. Dis. 1977, 136:717-723.
16. Groisman E.A., Parra-Lopez C., Salcedo M., Lipps C.J., Heffron F. Resistance to host antimicrobial peptides is necessary for Salmonella virulence. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:11939-11943.
17. Gunn J.S. Bacterial modification of LPS and resistance to antimicrobial peptides. J. Endotoxin Res. 2001, 7:57-62.
18. Hindle Z., Chatfield S.N., Phillimore J., Bentley M., Johnson J., Cosgrove C.A., Ghaem-Maghami M., Sexton A., Khan M., Brennan F.R., Everest P., Wu T., Pickard D., Holden D.W., Dougan G., Griffin G.E., House D., Santangelo J.D., Khan S.A., Shea J.E., Feldman R.G., Lewis D.J. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 2002, 70:3457-3467.
19. Hohmann E.L., Oletta C.A., Killeen K.P., Miller S.I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 1996, 173:1408-1414.
20. Hoiseth S.K., Stocker B.A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981, 291:238-239.
21. Hone D.M., Morona R., Attridge S., Hackett J. Construction of defined galE mutants of Salmonella for use as vaccines. J. Infect. Dis. 1987, 156:167-174.
22. Hone D.M., Attridge S.R., Forrest B., Morona R., Daniels D., LaBrooy J.T., Bartholomeusz R.C., Shearman D.J., Hackett J. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 1988, 56:1326-1333.
23. Hone D.M., Harris A.M., Chatfield S., Dougan G., Levine M.M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1991, 9:810-816.
24. Jones F., Axtell R.C., Tarver F.R., Rives D.V., Scheideler S.E., Wineland M.J. Experimental factors contributing to Salmonella colonization of chickens. Colonization Control of Human Bacterial Enteropathogens in Poultry 1991, 3-21. Academy Press, Inc, New York. L.C. Blankenship, J.S. Bailey, N.A. Cox, N.J. Stern, R.J. Meinersmann (Eds.).
25. Kang H.Y., Srinivasan J., Curtiss R. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar Typhimurium vaccine. Infect. Immun. 2002, 70:1739-1749.
26. Kirkpatrick B.D., Tenney K.M., Larsson C.J., O'Neill J.P., Ventrone C., Bentley M., Upton A., Hindle Z., Fidler C., Kutzko D., Holdridge R., Lapointe C., Hamlet S., Chatfield S.N. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J. Infect. Dis. 2005, 192:360-366.
27. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
28. Lawley T.D., Bouley D.M., Hoy Y.E., Gerke C., Relman D.A., Monack D.M. Host transmission of Salmonella enterica serovar Typhimurium is controlled by virulence factors and indigenous intestinal microbiota. Infect. Immun. 2008, 76:403-416.
29. Levine M.M., Herrington D., Murphy J.R., Morris J.G., Losonsky G., Tall B., et al. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J. Clin. Invest. 1987, 79:888-902.
30. 10 colony-forming units. Vaccine 2010, 28:3602-3608.
31. Mäkelä P.H., Stocker B.A. How genes determine the structure of the Salmonella lipopolysaccharide. J. Gen. Microbiol. 1969, 57:vi.
32. Muldoon M.T., Li J., Sutzko M., Olsson-Allen A.C., Teaney G., Gonzalez V. RapidChek SELECT Salmonella. Performance tested method 080601. J. AOAC Int. 2009, 92:1890-1894.
33. Muller H.E. A comparison of methods for the enrichment of Salmonellae from human feces. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 1982, 253:183-196.
34. Robbe-Saule V., Coynault C., Norel F. The live oral typhoid vaccine Ty21a is a rpoS mutant and is susceptible to various environmental stresses. FEMS Microbiol. Lett. 1995, 126:171-176.
35. Sambrook J., Russell D. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
36. Santander J., Wanda S.Y., Nickerson C.A., Curtiss R. Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi. Infect. Immun. 2007, 75:1382-1392.
37. Shi H., Santander J., Brenneman K.E., Wanda S.Y., Wang S., Senechal P., Sun W., Roland K.L., Curtiss R. Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS One 2010, 5:e11142.
38. Tacket C.O., Levine M.M. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin. Infect. Dis. 2007, 45(Suppl. 1):S20-S23.
39. Tacket C.O., Hone D.M., Curtiss R., Kelly S.M., Losonsky G., Guers L., Harris A.M., Edelman R., Levine M.M. Comparison of the safety and immunogenicity of δaroC δaroD and δcya δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 1992, 60:536-541.
40. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Nataro J.P., Edelman R., Pickard D., Dougan G., Chatfield S.N., Levine M.M. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 1997, 65:452-456.
41. Tacket C.O., Sztein M.B., Wasserman S.S., Losonsky G., Kotloff K.L., Wyant T.L., Nataro J.P., Edelman R., Perry J., Bedford P., Brown D., Chatfield S., Dougan G., Levine M.M. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 2000, 68:1196-1201.
42. Tsai C.M., Frasch C.E. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 1982, 119:115-119.
43. Tully J.G., Currie J.A. Vi-negative strains of Salmonella typhosa: attempts to induce W-V reversion and the use of non-Vi strains in evaluating typhoid vaccines. J. Bacteriol. 1962, 84:747-753.
44. van Velkinburgh J.C., Gunn J.S. PhoP-PhoQ-regulated loci are required for enhanced bile resistance in Salmonella spp. Infect. Immun. 1999, 67:1614-1622.
45. Vogelsang T.M., Boe J. Temporary and chronic carriers of Salmonella typhi and Salmonella paratyphi B. J. Hyg. (Lond.) 1948, 46:252-261.
46. Wahdan M.H., Sippel J.E., Mikhail I.A., Rahka A.E., Anderson E.S., Sparks H.A., Cvjetanovic B. Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2. Bull. World Health Organ. 1975, 52:69-73.
47. Wahdan M.H., Serie C., Germanier R., Lackany A., Cerisier Y., Guerin N., Sallam S., Geoffroy P., el Tantawi A.S., Guesry P. A controlled field trial of live oral typhoid vaccine Ty21a. Bull. World Health Organ. 1980, 58:469-474.
48. Wang R.F., Kushner S.R. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 1991, 100:195-199.
49. Xin W., Wanda S.Y., Li Y., Wang S., Mo H., Curtiss R. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect. Immun. 2008, 76:3241-3254.